Despite the high prevalence of CUD and its negative consequences, there are currently no FDA-approved medications
Glucagon-like peptide-1 receptor agonists, commonly referred to as GLP-1s, are becoming increasingly widespread, with the most notable examples including Ozempic, Wegovy, and Saxenda
Indeed, a large-scale 2014 study analysed a cohort of 10 040 patients with vitiligo to assess their risk of skin cancer compared with a control group
"GI intolerance with GLP-1 RA use is a big deal
The apparent physiological opposition between GLP-1 and GCG does not preclude pharmacological synergy, since GLP-1/GCG dual agonists are engineered to achieve balanced receptor activation rather than simple co-administration of two counter-regulatory hormones (61,64)